Bone Disease After Kidney Transplantation
Bone disease in kidney transplant recipients is a complex condition in which the long-term effects of immunosuppression are layered on top of pre-existing chronic kidney disease–Mineral and Bone Disorder (CKD-MBD). Post-transplant bone disease is multifactorial, involving prior skeletal damage, impaired graft function, and medication-related toxicity.
- Monitoring and Assessment
Monitoring needs evolve from the immediate post-operative period to long-term follow-up.
- Immediate Post-Operative Period:
Serum calcium and phosphorus should be checked at least weekly until stable. - Long-Term Follow-Up:
The frequency of monitoring calcium, phosphorus, and parathyroid hormone (PTH) should be individualized based on the severity of abnormalities and the rate of CKD progression. - DEXA Scanning:
For patients with eGFR >30 mL/min, DEXA scanning is suggested within the first 3 months if they are on long-term steroids or have other osteoporosis risk factors.
However, BMD testing is not routinely recommended in CKD stages 4–5T because it does not reliably predict fracture risk or distinguish types of renal bone disease.
- Osteoporosis and Fracture Risk
Fracture risk is high in transplant recipients, but prediction remains challenging because standard tools are not fully validated in this population.
- Primary Determinant:
Corticosteroids are the major driver of increased bone turnover and bone loss.
Steroid-sparing or steroid-withdrawal regimens are suggested for patients at high risk. - General Treatment:
Adults with low BMD in the first 12 months may be considered for vitamin D, calcitriol, or bisphosphonate therapy. - Bisphosphonate Caution:
Bisphosphonates (e.g., alendronate, pamidronate) are contraindicated when eGFR <30 mL/min.
Because they may cause adynamic bone disease, a bone biopsy may be considered before initiating therapy.
- Tertiary Hyperparathyroidism
Persistent hyperparathyroidism from the dialysis period may continue after transplantation and can cause significant hypercalcemia.
- Pre-Transplant:
Severe hyperparathyroidism should ideally be treated before transplantation. - Pharmacotherapy:
Cinacalcet can be used to correct hypercalcemia and elevated PTH levels and may improve bone mineral density. - Surgical Options:
Parathyroidectomy is effective for refractory cases but carries surgical risks that must be carefully weighed.
- Specialized Bone Complications
- Calcineurin Inhibitor (CNI)–Induced Bone Pain:
This syndrome typically affects the lower legs and may appear as bone marrow edema on MRI.
Management includes reducing CNI levels or using dihydropyridine calcium channel blockers.
• Denosumab:
This monoclonal antibody appears safe for preserving BMD in transplant recipients.
However, it requires close monitoring for hypocalcemia and has been associated with a higher incidence of urinary tract infections.
